Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Propanc Biopharma ( (PPCB) ) is now available.
On August 14, 2025, Propanc Biopharma entered into an underwriting agreement with D. Boral Capital for a public offering of 1,000,000 shares of common stock at $4.00 per share, raising $4 million in gross proceeds. The offering was completed on August 18, 2025, with net proceeds of $3.34 million after expenses. The company’s stock was approved for listing on the Nasdaq Capital Market under the symbol ‘PPCB’, beginning trading on August 15, 2025. Additionally, Propanc appointed Joseph Himy and Annie VanBroekhoven as independent directors, who will serve on various committees.
More about Propanc Biopharma
Propanc Biopharma, Inc. is a biopharmaceutical company focused on developing novel cancer treatments targeting the recurrence and metastasis of solid tumors. The company’s approach involves using pancreatic proenzymes to target and eradicate cancer stem cells, particularly in pancreatic, ovarian, and colorectal cancers.
Average Trading Volume: 1,494,613
Technical Sentiment Signal: Sell
Current Market Cap: $33.33M
For detailed information about PPCB stock, go to TipRanks’ Stock Analysis page.